

Table 6. Anti-HIV-1 activity of BMS-378806 against 83 clinical isolates from different envelope subtypes

HIV-1	Group	Subtype	Coreceptor Usage	NSI/SI	Country	EC ₅₀ *, nM		
						Mean	SD	
92RW026	M	A	R5	NSI	Rwanda	51.3	9.7	
94UG103					Uganda	466	24	
93RW020					Rwanda	1,132	121	
92UG029				SI	Uganda	2,010	171	
92UG031				R5	NSI	Uganda	>5,000	
93USBMS002			B	R5		USA	1	1
ASM44				R5/X4		USA	1.5	0.1
93BR023						Brazil	2.3	0.8
28MDR						USA	<2.7	
93USBMS003				R5		USA	3.5	0.04
93US157					NSI	USA	3.9	1.8
01USBMS028						USA	4.7	0.9
93US159				R5	NSI	USA	5.9	0.1
93US149				R5	NSI	USA	11.4	6.8
93US140					NSI	USA	11.9	4.9
93BR013						Brazil	12.4	5.3
00USBMS023						USA	18	5.3
ASM57				R5	NSI	USA	18.6	6.6
00USBMS024						USA	24	0.3
ASM34				R5		USA	24.4	0.3
92BR030				R5		Brazil	26	12
93USBMS001				X4		USA	35.8	5.1
91USBMS003					NSI	USA	39.8	12.1
92US657				R5	NSI	USA	43.1	22.2
00USBMS025						USA	60.5	22.9
92BR014				R5X4		Brazil	61	2
93US075				R5	NSI	USA	61.9	33.9
91US054					SI	USA	70.1	1.5
00USBMS020				R5X4		USA	113	37
92US073				R5	NSI	USA	129	57
92US056				R5	NSI	USA	165	15
93US143				SI	USA	166	7	
92HT593		R5X4		SI	Haiti	188	11	
411-1-C				NSI	USA	193	2	
92US715		R5		NSI	USA	>200		
92HT599			SI	Haiti	270	146		
92US072			NSI	USA	336	48		
ME46		R5X4		USA	545	92		
QZ4589		R5		USA	552	28		
91US005			NSI	USA	793	274		
93US141			NSI	USA	>800			
92US660			NSI	USA	1,076	363		
92US076			SI	USA	1,133	506		
00USBMS026				USA	>2,000			

HIV-1	Group	Subtype	Coreceptor Usage	NSI/SI	Country	EC ₅₀ *, nM			
						Mean	SD		
91USBMS004	M	B		SI	USA	>5,000			
W0				NSI	USA	≥5,914			
ME1			R5		USA	>10,000			
99ZABMS016		C				S. Africa	11.8	6.6	
99ZABMS014						S. Africa	16.2	0.8	
99ZABMS019						S. Africa	39.5	19	
99ZABMS020						S. Africa	79.5	39	
99ZABMS017						S. Africa	81.5	24	
99ZABMS015						S. Africa	220	96	
98BR004						Brazil	266	121	
93MW959			R5	NSI		Malawi	319	203	
98CN006				SI		China	355	282	
98IN101			R5	NSI		India	624	41	
98MW959			R5	NSI		Malawi	638	347	
99ZABMS018						S. Africa	749	124	
94UG114			D			NSI	Uganda	45.8	25.1
93UG065				X4	SI		Uganda	76.6	2.4
93UG067				R5X4	SI		Uganda	367	88
94UG105				SI		Uganda	688	242	
94UG117				SI		Uganda	>2,000		
93UG024		X4		SI		Uganda	>2,000		
93UG070		R5X4				Uganda	2,128	1,211	
94UG108		R5		NSI		Uganda	2,238	654	
93UG059		X4				Uganda	7,188	85	
93UG086		R5X4				Uganda	>10,000		
92TH009		E		R5	NSI		Thailand	>2,000	
CMU06					SI		Thailand	>2,000	
CMU10				NSI		Thailand	>2,000		
92TH020				NSI		Thailand	>2,000		
92TH019			R5	NSI		Thailand	>5,000		
02TH051	R5X4				Thailand	>10,000			
92BR029	F	R5	NSI		Brazil	214	51		
93BR020		R5X4			Brazil	>2,000			
93BR019		R5	NSI		Brazil	>5,000			
JV1083	G			NSI	Nigeria	>2,000			
RU570		R5	NSI		Russia	>2,000			
RU132		R5	NSI		Russia	4,290	1,120		
BCF01	O		R5	NSI	Cameroon	>2,000			
BCF03			R5	NSI	Cameroon	>2,000			

NSI, Non-syncytium-inducing; SI, syncytium-inducing.

*Antiviral end point: p24. All results were based on two to four replicates. SD, standard deviation.